Chartwell Drug Patent Portfolio
Chartwell owns 1 orange book drug protected by 2 US patents Given below is the list of Chartwell's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9492384 | Microemulsion and sub-micron emulsion process and compositions | 31 Aug, 2025 | Expired |
| US5690923 | Stable topical retinoid compositions | 25 Nov, 2014 | Expired |
Latest Legal Activities on Chartwell's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Chartwell.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Apr, 2024 | US9492384 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Apr, 2020 | US9492384 |
|
Recordation of Patent Grant Mailed
Critical
| 15 Nov, 2016 | US9492384 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 15 Nov, 2016 | US9492384 |
|
Email Notification
Critical
| 27 Oct, 2016 | US9492384 |
|
Issue Notification Mailed
Critical
| 26 Oct, 2016 | US9492384 |
| Dispatch to FDC | 17 Oct, 2016 | US9492384 |
|
Application Is Considered Ready for Issue
Critical
| 14 Oct, 2016 | US9492384 |
|
Issue Fee Payment Verified
Critical
| 13 Oct, 2016 | US9492384 |
|
Issue Fee Payment Received
Critical
| 13 Oct, 2016 | US9492384 |
| Mailing Corrected Notice of Allowability | 02 Aug, 2016 | US9492384 |
| Printer Rush- No mailing | 02 Aug, 2016 | US9492384 |
|
Email Notification
Critical
| 02 Aug, 2016 | US9492384 |
| Corrected Notice of Allowability | 28 Jul, 2016 | US9492384 |
|
Pubs Case Remand to TC
Critical
| 27 Jul, 2016 | US9492384 |
Chartwell Drug Patents' Oppositions Filed in EPO
Chartwell drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 14, 2014, by Generics [Uk] Limited. This opposition was filed on patent number EP05775966A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP05775966A | May, 2014 | Henkel AG & Co. KGaA | Patent maintained as amended |
| EP05775966A | May, 2014 | Generics [UK] Limited | Patent maintained as amended |
Chartwell's Family Patents
Recent FDA approvals and tentative approvals for Chartwell
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Bosentan |
SUPPL-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | REMS | 19 Jan, 2023 |
| Pramipexole Dihydrochloride |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 04 Dec, 2014 |
| Irbesartan And Hydrochlorothiazide |
ORIG-2
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Not Applicable | 27 Feb, 2013 |
Chartwell Drug List
Given below is the complete list of Chartwell's drugs and the patents protecting them.
1. Veltin
Veltin is protected by 2 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9492384 | Microemulsion and sub-micron emulsion process and compositions |
31 Aug, 2025
(10 months ago)
| Expired |
| US5690923 | Stable topical retinoid compositions |
25 Nov, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Veltin's drug page